Monopar Therapeutics (NASDAQ:MNPR) Stock Rating Upgraded by Wall Street Zen

Key Points

• Wall Street Zen upgraded Monopar Therapeutics from “sell” to “hold,” while the broader analyst consensus remains “Moderate Buy” with an average price target of $120.08.
• MNPR opened at $110.26, near its $120.08 consensus target, with a market capitalization of approximately $740 million and a 12-month trading range of $45.52 to $124.82.
• The company reported a quarterly loss of $0.62 per share, slightly better than the $0.64 estimate. Two directors recently sold shares under pre-arranged Rule 10b5-1 trading plans, and insiders own 9.70% of the company.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) was upgraded by analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a research report issued to clients and investors on Saturday, Wall Street Zen reports.

Other equities analysts have also issued research reports about the stock. Piper Sandler set a $105.00 price objective on shares of Monopar Therapeutics in a research report on Tuesday, June 2nd. UBS Group set a $125.00 price objective on shares of Monopar Therapeutics in a research note on Thursday, July 23rd. Weiss Ratings restated a "sell (d-)" rating on shares of Monopar Therapeutics in a research report on Friday, July 17th. Zacks Research cut shares of Monopar Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Thursday, August 13th. Finally, HC Wainwright boosted their price target on Monopar Therapeutics from $105.00 to $125.00 and gave the company a "buy" rating in a report on Wednesday, July 22nd. Two analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $120.08.

Monopar Therapeutics Price Performance

MNPR stock opened at $110.26 on Friday. The company's 50 day simple moving average is $111.51 and its 200-day simple moving average is $79.07. The firm has a market capitalization of $740.07 million, a PE ratio of -50.81 and a beta of 1.49. Monopar Therapeutics has a 12 month low of $45.52 and a 12 month high of $124.82.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($0.62) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.64) by $0.02. As a group, sell-side analysts anticipate that Monopar Therapeutics will post -2.94 earnings per share for the current year.

Insider Transactions at Monopar Therapeutics

In other news, Director Kim Tsuchimoto sold 4,090 shares of the stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $111.39, for a total transaction of $455,585.10. Following the transaction, the director directly owned 7,396 shares in the company, valued at $823,840.44. This represents a 35.61% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Raymond Anderson sold 3,142 shares of the firm's stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $111.77, for a total transaction of $351,181.34. Following the completion of the sale, the director directly owned 23,751 shares in the company, valued at $2,654,649.27. This represents a 11.68% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 9.70% of the company's stock.

Hedge Funds Weigh In On Monopar Therapeutics

A number of hedge funds have recently made changes to their positions in MNPR. Russell Investments Group Ltd. acquired a new stake in shares of Monopar Therapeutics during the 3rd quarter worth $28,000. BNP Paribas Financial Markets boosted its holdings in Monopar Therapeutics by 100.6% in the third quarter. BNP Paribas Financial Markets now owns 696 shares of the company's stock valued at $57,000 after acquiring an additional 349 shares during the last quarter. Sei Investments Co. grew its position in Monopar Therapeutics by 9.5% during the first quarter. Sei Investments Co. now owns 7,582 shares of the company's stock valued at $415,000 after acquiring an additional 656 shares during the period. Meeder Asset Management Inc. purchased a new stake in Monopar Therapeutics during the fourth quarter valued at about $65,000. Finally, Caitong International Asset Management Co. Ltd acquired a new stake in Monopar Therapeutics during the fourth quarter worth about $86,000. Institutional investors and hedge funds own 1.83% of the company's stock.

Monopar Therapeutics Company Profile

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company's core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company's pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.